Mohammad Oves*
Developing drug-loaded nanoparticles that bind to hydroxyapatite (HA) and can be used to make bone graft substitutes that release medications or growth hormones was the aim of this research. To do this, the non-ionic surfactant Brij 78 (polyoxyethylene (20) steady ether) was first modified using pamidronate (Pa). Pa-Brij 78 was used as a surfactant and an affinity ligand to HA to construct three different types of Pa surface functionalized nanoparticles: solid lipid nanoparticles (Pa-SNPs), nanoemulsions (Pa-NEMs), and PLGA nanoparticles (Pa- PNPs). The model drug curcumin was successfully encapsulated using the three nanoparticles. Pa-NEM, Pa-PNP, and Pa-SNP all had widths of about 150 nm and polydispersity indices (PDIs) less than 0.20. The drug encapsulation efficiency rates of the three nanoparticles were all greater than 85%. Additionally, this order was determined by the nanoparticles' affinity for attaching to HA. Although the three nanoparticles' affinities for binding to HA were roughly equal to those of newly made nanoparticles, their diameters were increased by 0.5-2.0 fold following lyophilization. A Pa-modified Brij 78 was synthesised and used in the production of many drug-loaded nanoparticles in order to develop drug-eluting HA-based bone graft substitutes.
KeywordsDrug development; Drug discovery; Drug designing; Nanoparticle; Nonionic surfactant
English 
Spanish 
Chinese 
German 
French 
Japanese 
Portuguese 
Hindi